The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Professor Yvonne Bryson of the University of California Los Angeles described the new case at the conference and an accompanying press briefing. The middle-aged (post-menopausal) woman, a participant ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

Scientists from the pharmaceutical company Merck have published the first detailed data about a subset of the familiar non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs that, in addition to ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

In a session at the 24th International AIDS Conference (AIDS 2022) last week, priorities and lessons learnt from the harm reduction programmes for people who inject drugs in Africa were discussed by a ...

A man dubbed the 'Geneva patient' appears to be the latest person cured of HIV after a stem cell transplant for cancer treatment. Unlike the other five known cases, however, he received stem cells ...

Now, in what its authors describe as an “exploratory and descriptive study”, figures from different agencies have been pulled together to paint a picture of HIV in this vast country. The analysis, by ...

The British HIV Association (BHIVA) conference in Gateshead this week heard the results of the first year’s rollout of opt-out testing for HIV and hepatitis B and C for all patients attending ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...